Tyra Biosciences (NASDAQ:TYRA) Given Outperform Rating at Wedbush

Wedbush restated their outperform rating on shares of Tyra Biosciences (NASDAQ:TYRA) in a report issued on Friday, Benzinga reports. Wedbush currently has a $28.00 price target on the stock.

Several other research analysts also recently commented on the stock. Bank of America raised shares of Tyra Biosciences from a “neutral” rating to a “buy” rating and raised their price target for the stock from $22.00 to $31.00 in a research note on Friday, October 18th. Piper Sandler assumed coverage on shares of Tyra Biosciences in a research report on Thursday, August 15th. They set an “overweight” rating and a $33.00 target price on the stock. HC Wainwright raised their target price on shares of Tyra Biosciences from $25.00 to $30.00 and gave the company a “buy” rating in a research report on Monday, October 7th. Finally, Oppenheimer raised their target price on shares of Tyra Biosciences from $25.00 to $33.00 and gave the company an “outperform” rating in a research report on Thursday, September 19th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $31.00.

Tyra Biosciences Stock Down 23.3 %

TYRA stock traded down $6.68 during trading on Friday, hitting $21.93. The company had a trading volume of 2,482,484 shares, compared to its average volume of 166,105. The firm has a market capitalization of $1.16 billion, a P/E ratio of -12.98 and a beta of 1.01. Tyra Biosciences has a 52-week low of $10.38 and a 52-week high of $29.60. The company has a 50 day simple moving average of $22.89 and a 200-day simple moving average of $19.82.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.09. Sell-side analysts forecast that Tyra Biosciences will post -1.53 earnings per share for the current year.

Insider Transactions at Tyra Biosciences

In other news, CEO Todd Harris sold 10,092 shares of Tyra Biosciences stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $24.13, for a total value of $243,519.96. Following the transaction, the chief executive officer now owns 1,479,528 shares of the company’s stock, valued at $35,701,010.64. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold a total of 61,403 shares of company stock valued at $1,582,774 in the last 90 days. Insiders own 15.40% of the company’s stock.

Institutional Trading of Tyra Biosciences

Institutional investors have recently bought and sold shares of the stock. SG Americas Securities LLC acquired a new stake in Tyra Biosciences in the 3rd quarter worth approximately $311,000. HighVista Strategies LLC acquired a new stake in Tyra Biosciences in the 2nd quarter worth approximately $257,000. Rhumbline Advisers boosted its stake in Tyra Biosciences by 12.3% in the 2nd quarter. Rhumbline Advisers now owns 23,572 shares of the company’s stock worth $377,000 after purchasing an additional 2,574 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Tyra Biosciences by 32.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 58,087 shares of the company’s stock worth $929,000 after purchasing an additional 14,352 shares in the last quarter. Finally, Oppenheimer & Co. Inc. acquired a new stake in Tyra Biosciences in the 1st quarter worth approximately $977,000. 84.14% of the stock is currently owned by institutional investors and hedge funds.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.